Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials   << Read the release >>

Empowering Myeloid Cells to Fight Disease

Myeloid Therapeutics is reprogramming myeloid cells to harness their potent immune activity and to enhance clinical outcomes in cancer and other diseases.

Developed by leading scientists and clinicians who specialize in oncology, immunology, cell therapy, synthetic biology, and translational medicine, Myeloid’s proprietary ATAK™ platform, mRNA & tri-specific biologic technologies redirect & reprogram cells of the innate immune system to kill cancer.

Our therapies incorporate advanced methods in cell & gene therapy, combining immunology, genetics, cell biology & protein science to improve the lives of patients in need.

Myeloid Therapeutics is unleashing the power of innate cells for cancer therapy.

The company is planning multiple Phase I clinical trials in 2021, starting with glioblastoma and T cell lymphomas.

Discovery

Lead 

Optimization

IND Enabling

Phase I 

MT-201

Glioblastoma 

MT-101

T Cell Lymphoma

MT-102

HER2+ Solid Tumors

MT-103

TROP2 Solid Tumors

© 2020,   Myeloid Therapeutics.  All rights reserved.                 Privacy Policy     |     Terms of Use     |      Cookie Policy

  • LinkedIn
  • Instagram
  • Twitter

300 Technology Square, Suite 203      |      Cambridge, Massachusetts 02139